NVCT
NASDAQNuvectis Pharma Inc.
Price$27.18-0.76 (-2.70%)
01:30 PM07:45 PM
News · 26 weeks23+75%
2025-12-282026-06-21
Mix1490d
- SEC Filings6(43%)
- Insider4(29%)
- Other3(21%)
- Earnings1(7%)
Latest news
25 items- SECNuvectis Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage CompoundsThe transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor (CFBi [NXP100]) and also enhances the oncology product pipeline with the in-licensing of a paradox breaker BRAF inhibitor (BRAFi [NXP200]) for the treatment of BRAF-mutated malignancies.NXP100 (HSK39297): A once-daily, oral CFBi in late-stage development for the treatment of complement-mediated diseases. Current development status in China includes:Two Marketing Authorization Applications (MAAs) are under review for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH); The applications see
- INSIDERDirector Hoberman Kenneth was granted 35,000 shares, increasing direct ownership by 26% to 168,140 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERDirector Oliviero James F Iii was granted 35,000 shares, increasing direct ownership by 40% to 122,828 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERDirector Sanchez Juan was granted 35,000 shares, increasing direct ownership by 45% to 113,380 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERDirector Kaplan Matthew L. was granted 35,000 shares, increasing direct ownership by 28% to 159,760 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQFort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York. Conference Details: Date: Tuesday, May 19, 2026Company Presentation: 9:00 – 9:30AM EDTPresenter: Ron Bentsur, Chairman and Chief Executive Officer of NuvectisWebcast Link: hereLocation: New York, NY A webcast of the presentation will be avai
- SECSEC Form 10-Q filed by Nuvectis Pharma Inc.10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business HighlightsNXP900 Phase 1b clinical program continues to enroll patients at select sites in the USNXP900 preclinical presentations at the 2026 American Association for Cancer Research ("AACR") Annual Meeting" further support the clinical development strategy FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Ex
- SECSEC Form DEFA14A filed by Nuvectis Pharma Inc.DEFA14A - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECSEC Form DEF 14A filed by Nuvectis Pharma Inc.DEF 14A - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research MeetingFort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP900 at the upcoming 2026 American Association for Cancer Research Meeting (2026 AACR), taking place from April 17th to April 22nd in San Diego, CA. Abstract TitlePoster Presentation DetailsNXP900, a Phase 1b, first-in-class YES1/SRC inhibitor demonstrates potent synergy with KRAS inhibitors in KRASi sensitive and resistant NSCLC modelsSession TitleCombina
- SECSEC Form EFFECT filed by Nuvectis Pharma Inc.EFFECT - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECSEC Form S-3 filed by Nuvectis Pharma Inc.S-3 - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECSEC Form 10-K filed by Nuvectis Pharma Inc.10-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma, Inc. Reports 2025 Financial Results and Business HighlightsFORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "2025 was an eventful year for Nuvectis, with significant progress made in the NXP900 development program, laying the groundwork for multiple potential data readouts in 2026. Our Phase 1b monotherapy s
- INSIDERChief Dev. & Ops. Officer Shemesh Shay was granted 150,000 shares, increasing direct ownership by 9% to 1,793,068 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERChairman & CEO Bentsur Ron was granted 150,000 shares, increasing direct ownership by 4% to 3,675,924 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERChief Science & Business Off Poradosu Enrique was granted 150,000 shares, increasing direct ownership by 9% to 1,806,319 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERVice President, Finance Carson Michael J. was granted 61,200 shares, increasing direct ownership by 44% to 200,118 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- PRNuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLCFort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is a potent inhibitor of the SRC and YES1kinases. The brand name for Osimertinib is Tagrisso®, marketed by Astra Zeneca. Tagrisso, a 3rd generation EGFR inhibitor is broadly used in patients with NSCLCmut+ as single agent or in combination with chemotherapy a
- PRNuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLCFort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT, the "Company")), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, including the combination with osimertinib in non-small cell lung cancer. To register for the event, click here. The event will feature Alexander Spira, MD, PhD, FACP, FASCO (Chief Scientific Officer, NEXT Oncology) and Asier Unc
NVCT FAQ
7 questionsWhat does Nuvectis Pharma Inc. do?
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.Where does NVCT stock trade?
Nuvectis Pharma Inc. (NVCT) is listed on NASDAQ.What sector and industry is NVCT in?
Nuvectis Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nuvectis Pharma Inc. go public?
Nuvectis Pharma Inc. (NVCT) completed its IPO in 2022.What are analysts saying about NVCT?
Nuvectis Pharma Inc. has had 4 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $1700.00 price target on 2025-04-02. Recent price targets range from $1400.00 to $2100.00.What companies are similar to NVCT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NVCT side-by-side with any of them on Quantisnow.How can I track NVCT on Quantisnow?
Quantisnow aggregates Nuvectis Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVCT to receive live email and push alerts on every new disclosure.